PDS BIOTECHNOLOGY CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.38 USD | -5.06% |
|
-3.43% | -31.99% |
| 05-15 | PDS Biotechnology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 05-10 | NetScientific says PDS Biotech's Versamune meets endpoints | AN |
Presentation Operator MessageOperator (Operator)Hello, and welcome to the PDS Biotechnology In...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
Calendar
2024-06-24
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
3.38
USD
Average target price
13
USD
Spread / Average Target
+284.62%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -31.99% | 124M | |
| +9.99% | 115B | |
| +12.01% | 106B | |
| -3.07% | 24.69B | |
| -0.67% | 21.97B | |
| -4.64% | 19.27B | |
| -6.90% | 17.56B | |
| -39.36% | 17.32B | |
| +5.82% | 14.03B | |
| +33.05% | 12.13B |
- Stock Market
- Equities
- PDSB Stock
- News PDS Biotechnology Corporation
- Transcript : PDS Biotechnology Corporation - Special Call
